<...the next generation of human therapeutics>
What a frustrating game for investors--if the next
generation is always more interesting. If biotech
startups are only good for a few years til the next
round of startups emerges, with a new set of IPOs, burn,
repeat. And all that expensive great science--Genset's
SNP map, rendered mostly obsolete (?) by the Wellcome
trust, a protein library, nah, large scale proteomics
man! etc etc
So now maybe some new companies, Valigen for one--they
turn up the sex appeal, and sure, they do some great
science, they get their IPO, and then what. Five years
from now they pull a Genset.
Or the whole thing is phoney. If I have shares at $12
somebody else out there might as well get his at $6.
This is cute...my little daughter is tearing up my
special Nature, the Genome issue, heheh. Oh heck,
I tucked enough away that she is going to any school
she wants to many years from now, what is it to me
if the stocks I chose to keep are stinkers. I am
still the luckiest man I know, so goodnight everybody.
Best wishes finding the next hot stock. It ain't easy. |
